Clinical Trial: Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer

U.S., Feb. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07419880) titled 'Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer' on Jan. 23.

Brief Summary: RECLAIM: A Phase II, Open-Label, Single-Arm, Multicenter Clinical Trial of Cromolyn, TQB2102, and Panpulimab for Re-Challenging Immune-Refractory Triple-Negative Breast Cancer

Study Start Date: Jan. 30

Study Type: INTERVENTIONAL

Condition: Triple -Negative Breast Cancer

Intervention: DRUG: Cromolyn, TQB2102, and Panpulimab

Upon enrollment, patients will receive intravenous administration of penpulimab (200 mg) and TQB2102 (6 mg/kg) every three weeks, along with intranasal delivery of...